Verastem Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
April 02 2019 - 7:00AM
Business Wire
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company),
focused on developing and commercializing medicines to improve the
survival and quality of life of cancer patients, today announced
that the Company will present at the H.C. Wainwright Global Life
Sciences Conference on Tuesday, April 9, 2019 at 11:50 a.m. BST in
London, UK.
A live webcast of the presentation will be available on the
investors section of the Company’s website at www.verastem.com. An
archived presentation will be available for 90 days.
About Verastem Oncology
Verastem Oncology (Nasdaq:VSTM) is a commercial
biopharmaceutical company committed to the development and
commercialization of medicines to improve the lives of patients
diagnosed with cancer. We are driven by the strength, tenacity and
courage of those battling cancer – single-minded in our resolve to
deliver new therapies that not only keep cancer at bay, but improve
the lives of patients diagnosed with cancer. Because for us, it’s
personal.
Our first FDA approved product is now available for the
treatment of patients with certain types of indolent non-Hodgkin’s
lymphoma (iNHL). Our pipeline comprises product candidates that
seek to treat cancer by modulating the local tumor
microenvironment. For more information, please visit
www.verastem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190402005118/en/
Verastem Oncology:Rob GagnonChief Financial Officer+1
781-469-1681rgagnon@verastem.com
Investors:Joseph RayneArgot Partners+1
617-340-6075joseph@argotpartners.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Sep 2023 to Sep 2024